Jim Simons Biotechnology

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
IOVA Iovance Biotherapeutics, Inc.	$352M	$8.41 Million 0.01% of portfolio	4,887,200	Q2 2025 Added 39.18%
ZLAB Zai Lab LTD	$3.36B	$8.14 Million 0.01% of portfolio	232,900	Q2 2025 Added 175.62%
SNDX Syndax Pharmaceuticals Inc	$734M	$7.85 Million 0.01% of portfolio	837,700	Q2 2025 Added 22.93%
RARE Ultragenyx Pharmaceutical Inc.	$1.97B	$7.57 Million 0.01% of portfolio	208,300	Q2 2025 Reduced 30.47%
GERN Geron Corp	$510M	$7.05 Million 0.01% of portfolio	4,999,100	Q2 2025 Reduced 10.75%
IMCR Immunocore Holdings PLC	$1.4B	$6.97 Million 0.01% of portfolio	222,052	Q2 2025 Added 145.17%
IMVT Immunovant, Inc.	$3.55B	$6.64 Million 0.01% of portfolio	241,400	Q2 2025 Reduced 39.03%
DAWN Day One Biopharmaceuticals, Inc.	$451M	$6.5 Million 0.01% of portfolio	1,000,540	Q2 2025 Added 187.15%
PBYI Puma Biotechnology, Inc.	$222M	$6.43 Million 0.01% of portfolio	1,874,713	Q2 2025 Added 2.49%
NTLA Intellia Therapeutics, Inc.	$825M	$6.35 Million 0.01% of portfolio	676,900	Q2 2025 New
KURA Kura Oncology, Inc.	$415M	$6.1 Million 0.01% of portfolio	1,057,010	Q2 2025 Added 98.46%
RGNX Regenxbio Inc.	$350M	$6.04 Million 0.01% of portfolio	735,200	Q2 2025 Added 147.71%
ITOS I Teos Therapeutics, Inc.	$359M	$6 Million 0.01% of portfolio	602,100	Q2 2025 Reduced 6.74%
ETON Eton Pharmaceuticals, Inc.	$438M	$5.78 Million 0.01% of portfolio	405,900	Q2 2025 Added 48.14%
HRTX Heron Therapeutics, Inc.	$156M	$5.57 Million 0.01% of portfolio	2,689,339	Q2 2025 Added 18.24%
VIR Vir Biotechnology, Inc.	$578M	$5.37 Million 0.01% of portfolio	1,064,500	Q2 2025 Reduced 4.99%
MNKD Mannkind Corp	$942M	$5.28 Million 0.01% of portfolio	1,412,942	Q2 2025 Reduced 14.35%
RLAY Relay Therapeutics, Inc.	$403M	$5.22 Million 0.01% of portfolio	1,508,210	Q2 2025 Reduced 33.74%
ARDX Ardelyx, Inc.	$866M	$5.1 Million 0.01% of portfolio	1,301,193	Q2 2025 Reduced 3.73%
CNTA Centessa Pharmaceuticals PLC	$1.61B	$5.06 Million 0.01% of portfolio	384,900	Q2 2025 Added 116.24%
ETNB 89bio, Inc.	$420M	$5.04 Million 0.01% of portfolio	513,400	Q2 2025 Added 1.8%
AVIR Atea Pharmaceuticals, Inc.	$292M	$4.44 Million 0.01% of portfolio	1,234,100	Q2 2025 Reduced 3.47%
VIGL Vigil Neuroscience, Inc.	$228M	$4.26 Million 0.01% of portfolio	535,800	Q2 2025 Added 144.21%
CTMX Cytom X Therapeutics, Inc.	$123M	$4.23 Million 0.01% of portfolio	1,862,200	Q2 2025 Added 61.09%
NVAX Novavax Inc	$663M	$4.21 Million 0.01% of portfolio	667,647	Q2 2025 Added 32.14%
MREO Mereo Biopharma Group PLC	$207M	$4.01 Million 0.01% of portfolio	1,480,471	Q2 2025 Added 9.63%
AUTL Autolus Therapeutics PLC	$195M	$3.99 Million 0.01% of portfolio	1,751,200	Q2 2025 Added 10.55%
OCUL Ocular Therapeutix, Inc	$961M	$3.81 Million 0.01% of portfolio	410,048	Q2 2025 Reduced 9.68%
SGMO Sangamo Therapeutics, Inc	$81.4M	$3.69 Million 0.01% of portfolio	6,839,434	Q2 2025 Added 115.88%
CLDX Celldex Therapeutics, Inc.	$1.11B	$3.69 Million 0.01% of portfolio	181,388	Q2 2025 Added 23.74%
ENTA Enanta Pharmaceuticals Inc	$142M	$3.55 Million 0.01% of portfolio	469,500	Q2 2025 Added 1.27%
TERN Terns Pharmaceuticals, Inc.	$246M	$3.44 Million 0.0% of portfolio	922,534	Q2 2025 Reduced 35.66%
GOSS Gossamer Bio, Inc.	$181M	$3.36 Million 0.0% of portfolio	2,732,294	Q2 2025 Added 74.13%
MDGL Madrigal Pharmaceuticals, Inc.	$6.14B	$3.28 Million 0.0% of portfolio	10,836	Q2 2025 Reduced 87.26%
CDXC Chroma Dex Corp.	$420M	$3.01 Million 0.0% of portfolio	489,600	Q2 2025 Reduced 6.4%
RCUS Arcus Biosciences, Inc.	$698M	$3 Million 0.0% of portfolio	368,100	Q2 2025 Added 80.44%
KOD Kodiak Sciences Inc.	$443M	$2.85 Million 0.0% of portfolio	764,137	Q2 2025 Added 8.76%
GLUE Monte Rosa Therapeutics, Inc.	$208M	$2.77 Million 0.0% of portfolio	615,100	Q2 2025 Added 274.83%
DNLI Denali Therapeutics Inc.	$1.77B	$2.74 Million 0.0% of portfolio	195,700	Q2 2025 Added 13.06%
TRVI Trevi Therapeutics, Inc.	$428M	$2.68 Million 0.0% of portfolio	489,300	Q2 2025 Added 450.39%
TRDA Entrada Therapeutics, Inc.	$162M	$2.55 Million 0.0% of portfolio	379,500	Q2 2025 Added 15.53%
AMLX Amylyx Pharmaceuticals, Inc.	$481M	$2.54 Million 0.0% of portfolio	396,200	Q2 2025 Reduced 23.08%
CGEM Cullinan Oncology, Inc.	$332M	$2.52 Million 0.0% of portfolio	334,525	Q2 2025 Reduced 7.85%
SPRO Spero Therapeutics, Inc.	$82.8M	$2.41 Million 0.0% of portfolio	832,165	Q2 2025 Reduced 14.29%
SEER Seer, Inc.	$129M	$2.39 Million 0.0% of portfolio	1,117,710	Q2 2025 Added 35.31%
PLX Protalix Bio Therapeutics, Inc.	$81.6M	$2.39 Million 0.0% of portfolio	1,615,003	Q2 2025 Added 35.83%
CGEN Compugen LTD	$127M	$2.36 Million 0.0% of portfolio	1,327,100	Q2 2025 Reduced 4.89%
NUVL Nuvalent, Inc.	$3.29B	$2.23 Million 0.0% of portfolio	29,200	Q2 2025 Added 1.74%
BCYC Bicycle Therapeutics PLC	$214M	$2.21 Million 0.0% of portfolio	318,400	Q2 2025 Added 5.61%
ELYM Eliem Therapeutics, Inc.	$109M	$2.04 Million 0.0% of portfolio	495,500	Q2 2025 Reduced 3.67%

Shares Options

Jim Simons

Jim Simons is the founder and chairman of Renaissance Technologies, a successful investment firm that uses quantitative approaches to investing. Simons is known for his expertise in mathematical modeling and has a reputation for being a skilled and successful investor. He has generated strong returns for his clients over the long term.

Track Jim Simons's portfolio

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account